Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Staged Heart Procedures Best for Patients

By LabMedica International staff writers
Posted on 15 Aug 2013
Patients with coronary artery disease (CAD) who underwent carotid artery stenting (CAS) followed a few weeks later by open heart surgery (OHS) had a lower relative risk than those undergoing a combined procedure, according to a new study.

Researchers at the Cleveland Clinic (OH, USA) conducted a retrospective study of the records of 350 patients (mean age 71, 75% male) treated at the Cleveland Clinic from 1997 to 2009. More...
Of these, 45 underwent staged carotid endarterectomy (CEA) followed by OHS (CEA-OHS), 195 underwent combined CEA-OHS, and 110 staged CAS-OHS; median follow-up was 3.7 years. The primary composite end point was all-cause death, stroke, and myocardial infarction (MI).

The results showed that the relative reduced risk over a period longer than one year was 67% for staged stenting compared with staged endarterectomy, and 65% for staged stenting versus the combined procedure. The late difference was primarily driven by a higher all-cause mortality rate in the staged and combined CEA groups beyond one year of the index OHS. Staged CEA-OHS was also associated with the greatest short-term composite risk, mostly driven by the occurrence of MIs during the period between procedures. The study was published in the July 2013 issue of the Journal of the American College of Cardiology.

“Many physicians are uncomfortable with waiting four weeks to perform bypass surgery. Are we going to tell patients to wait until they have symptoms, which essentially are stroke or transient ischemic attack?” said lead author Mehdi Shishehbor, DO, MPH, PhD, director of endovascular services at the Cleveland Clinic. “Because patients don't want to wait, more than 95% of them will choose to undergo procedures that might not deliver the best results.”

The researchers added that the results are in concordance with the available literature in the US and Europe showing a consistent pattern favoring staged carotid stenting followed by bypass surgery. However, only 3% of patients in the US with concomitant severe carotid and coronary disease will choose CAS-OHS, since Medicare (Baltimore, MD, USA) mandates a 3- to 4-week waiting period after CAS and before open-heart surgery.

Related Links:

Cleveland Clinic
Medicare



Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gel Cards
DG Gel Cards
Capillary Blood Collection Tube
IMPROMINI M3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The addition of Biocare’s complementary IHC antibody, reagent and instrument portfolio enhances Agilent’s immunohistochemistry offering (Photo courtesy of Biocare Medical)

Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical

Agilent Technologies (Santa Clara, CA, USA) has entered into a definitive agreement to acquire Biocare Medical (Pacheco, CA, USA), expanding its pathology portfolio through the addition of highly complementary... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.